Clinical Trial Update: EFG vs IVIG in TAMG [Phase 3]

View source ↗

Summary

Phase 3 trial planned to compare efgartigimod against intravenous immunoglobulin in thymoma-associated myasthenia gravis, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis
• Thymoma-associated Myasthenia Gravis

Drugs mentioned

• Intravenous Immunoglobulin (IVIG)
• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Efgartigimod, Intravenous Immunoglobulin | Phase 3 | Status: NOT_YET_RECRUITING